Top

Published in:

01-09-2018

Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer

Authors: Peeyush K. Lala, Pinki Nandi, Mousumi Majumder

Published in: Cancer and Metastasis Reviews | Issue 2-3/2018

Abstract

Lymphangiogenesis (formation of new lymphatic vessels), unlike angiogenesis, has been a lesser-focused field in cancer biology, because of earlier controversy regarding whether lymphatic metastasis occurs via pre-existing or newly formed lymphatics. Recent evidence reveals that peri-tumoral or intra-tumoral lymphangiogenesis is a precursor for lymphatic metastasis in most carcinomas and melanomas. Two major lymphangiogenic factors, vascular endothelial growth factor (VEGF)-C and VEGF-D, are produced by cancer cells or immune cells such as macrophages in the tumor-stroma to promote sprouting of lymphatics from lymphatic endothelial cells (LEC) or LEC precursors (LECP) by binding to their primary (high affinity) receptor VEGF-R3 or secondary receptors VEGF-R2, neuropilin (NRP)2 and α9/β1 integrin. Many other growth factors/receptors such as VEGF-A/VEGF-R2, fibroblast growth factor (FGF)2/FGF-R, platelet-derived growth factor (PDGF)/PDGF-R, hepatocyte growth factor (HGF)/C-Met, angiopoietins (Ang)1, 2/Tie2, and chemokines/ chemokine receptors (CCL21/CCR7, CCL12/CCR4) can also stimulate LEC sprouting directly or indirectly. This review deals with the roles of prostaglandins (PG), in particular PGE2, in cancer-associated lymphangiogenesis, with special emphasis on breast cancer. We show that cyclooxygenase (COX)-2 expression by breast cancer cells or tumor stroma leading to high PGE2 levels in the tumor milieu promotes lymphangiogenesis and lymphatic metastases, resulting from binding of PGE2 to PGE receptors (EP, in particular EP4) on multiple cell types: tumor cells, tumor-infiltrating immune cells, and LEC. EP4 activation on cancer cells and macrophages upregulated VEGF-C/D production to stimulate LEC sprouting. Furthermore, ligation of EP4 with PGE2 on cancer or host cells can initiate a new cascade of molecular events leading to cross-talk between cancer cells and LEC, facilitating lymphangiogenesis and lympho-vascular transport of cancer cells. We make a case for EP4 as a potential therapeutic target for breast cancer.

Swartz, M. A., & Skobe, M. (2001). Lymphatic function, lymphangiogenesis, and cancer metastasis. Microscopy Research and Technique, 55(2), 92–99. https://doi.org/10.1002/jemt.1160.PubMedCrossRef

Alitalo, K., Tammela, T., & Petrova, T. V. (2005). Lymphangiogenesis in development and human disease. Nature, 438(7070), 946–953. https://doi.org/10.1038/nature04480.PubMedCrossRef

Cueni, L. N., & Detmar, M. (2008). The lymphatic system in health and disease. Lymphatic Research and Biology, 6(3-4), 109–122. https://doi.org/10.1089/lrb.2008.1008.PubMedPubMedCentralCrossRef

Tammela, T., & Alitalo, K. (2010). Lymphangiogenesis: molecular mechanisms and future promise. Cell, 140(4), 460–476. https://doi.org/10.1016/j.cell.2010.01.045.PubMedCrossRef

Ran, S., Volk, L., Hall, K., & Flister, M. J. (2010). Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology, 17(4), 229–251. https://doi.org/10.1016/j.pathophys.2009.11.003.PubMedCrossRef

Christiansen, A., & Detmar, M. (2011). Lymphangiogenesis and cancer. Genes & Cancer, 2(12), 1146–1158. https://doi.org/10.1177/1947601911423028.CrossRef

Rovenska, E., & Rovensky, J. (2011). Lymphatic vessels structure and function. IMAJ, 13(12), 762–768.PubMed

von der Weid, P. Y., & Zawieja, D. C. (2004). Lymphatic smooth muscle: the motor unit of lymph drainage. The International Journal of Biochemistry & Cell Biology, 36(7), 1147–1153. https://doi.org/10.1016/j.biocel.2003.12.008.CrossRef

Karkkainen, M. J., Haiko, P., Sainio, K., Partanen, J., Taipale, J., Petrova, T. V., et al. (2004). Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nature Immunology, 5(1), 74–80. https://doi.org/10.1038/ni1013.PubMedCrossRef

10.

Veikkola, T., Jussila, L., Makinen, T., Karpanen, T., Jeltsch, M., Petrova, T. V., et al. (2001). Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. The EMBO Journal, 20(6), 1223–1231. https://doi.org/10.1093/emboj/20.6.1223.PubMedPubMedCentralCrossRef

11.

Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X., Lakso, M., Rauvala, H., et al. (1997). Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science, 276(5317), 1423–1425. https://doi.org/10.1126/science.276.5317.1423.PubMedCrossRef

12.

Dumont, D. J., Jussila, L., Taipale, J., Lymboussaki, A., Mustonen, T., Pajusola, K., et al. (1998). Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science, 282(5390), 946–949. https://doi.org/10.1126/science.282.5390.946.PubMedCrossRef

13.

Vlahakis, N. E., Young, B. A., Atakilit, A., & Sheppard, D. (2005). The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin α9β1. The Journal of Biological Chemistry, 280(6), 4544–4552. https://doi.org/10.1074/jbc.M412816200.PubMedCrossRef

14.

Huang, X. Z., Wu, J. F., & Sheppard, D. (2000). Fatal bilateral chylothorax in mice lacking the integrin α9β1. Molecular and Cellular Biology, 20(14), 5208–5215. https://doi.org/10.1128/MCB.20.14.5208-5215.2000.PubMedPubMedCentralCrossRef

15.

Parker, M. W., Linkugel, A. D., Goel, H. L., Wu, T., Mercurio, A. M., & Vander Kooi, C. W. (2015). Structural basis for VEGF-C binding to neuropilin-2 and sequestration by a soluble splice form. Structure, 23(4), 677–687. https://doi.org/10.1016/j.str.2015.01.018.PubMedPubMedCentralCrossRef

16.

Yuan, L., Moyon, D., Pardanaud, L., Bréant, C., Karkkainen, M. J., Alitalo, K., et al. (2002). Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development, 129(20), 4797–4806.PubMed

17.

Baldwin, M. E., Halford, M. M., Roufail, S., Williams, R. A., Hibbs, M. L., Grail, D., et al. (2005). Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Molecular and Cellular Biology, 25(6), 2441–2449. https://doi.org/10.1128/MCB.25.6.2441-2449.2005.PubMedPubMedCentralCrossRef

18.

Karpanen, T., Egeblad, M., Karkkainen, M. J., Kubo, H., Yla-Herttuala, S., Jaattela, M., et al. (2001). Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Research, 61(5), 1786–1790.PubMed

19.

Kubo, H., Cao, R., Brakenhielm, E., Makinen, T., Cao, Y., & Alitalo, K. (2002). Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proceedings of the National Academy of Sciences of the United States of America, 99(13), 8868–8873. https://doi.org/10.1073/pnas.062040199.PubMedPubMedCentralCrossRef

20.

Chang, L. K., Garcia-Cardena, G., Farnebo, F., Fannon, M., Chen, E. J., Butterfield, C., et al. (2004). Dose-dependent response of FGF-2 for lymphangiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 101(32), 11658–11663. https://doi.org/10.1073/pnas.0404272101.PubMedPubMedCentralCrossRef

21.

Cao, R., Bjorndahl, M. A., Religa, P., Clasper, S., Garvin, S., Galter, D., et al. (2004). PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell, 6(4), 333–345. https://doi.org/10.1016/j.ccr.2004.08.034.PubMedCrossRef

22.

Cao, R., Eriksson, A., Kubo, H., Alitalo, K., Cao, Y., & Thyberg, J. (2004). Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circulation Research, 94(5), 664–670. https://doi.org/10.1161/01.RES.0000118600.91698.BB.PubMedCrossRef

23.

Hirakawa, S., Kodama, S., Kunstfeld, R., Kajiya, K., Brown, L. F., & Detmar, M. (2005). VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. The Journal of Experimental Medicine, 201(7), 1089–1099. https://doi.org/10.1084/jem.20041896.PubMedPubMedCentralCrossRef

24.

Bjorndahl, M. A., Cao, R., Burton, J. B., Brakenhielm, E., Religa, P., Galter, D., et al. (2005). Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Research, 65(20), 9261–9268. https://doi.org/10.1158/0008-5472.CAN-04-2345.PubMedCrossRef

25.

Kajiya, K., Hirakawa, S., Ma, B., Drinnenberg, I., & Detmar, M. (2005). Hepatocyte growth factor promotes lymphatic vessel formation and function. The EMBO Journal, 24(16), 2885–2895. https://doi.org/10.1038/sj.emboj.7600763.PubMedPubMedCentralCrossRef

26.

Morisada, T., Oike, Y., Yamada, Y., Urano, T., Akao, M., Kubota, Y., et al. (2005). Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood, 105(12), 4649–4656. https://doi.org/10.1182/blood-2004-08-3382.PubMedCrossRef

27.

Paduch, R. (2016). The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cellular Oncology (Dordrecht), 39(5), 397–410. https://doi.org/10.1007/s13402-016-0281-9.CrossRef

28.

Neufeld, G., & Kessler, O. (2008). The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nature Reviews. Cancer, 8(8), 632–645. https://doi.org/10.1038/nrc2404.PubMedCrossRef

29.

Singh, N., Tiem, M., Watkins, R., Cho, Y. K., Wang, Y., Olsen, T., et al. (2013). Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity. Blood, 121(20), 4242–4249. https://doi.org/10.1182/blood-2012-08-453043.PubMedPubMedCentralCrossRef

30.

Ran, S., & Montgomery, K. E. (2012). Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers (Basel), 4(3), 618–657. https://doi.org/10.3390/cancers4030618.CrossRef

31.

Cooley, L. S., Handsley, M. M., Zhou, Z., Lafleur, M. A., Pennington, C. J., Thompson, E. W., et al. (2010). Reversible transdifferentiation of blood vascular endothelial cells to a lymphatic-like phenotype in vitro. Journal of Cell Science, 123(Pt 21), 3808–3816. https://doi.org/10.1242/jcs.064279. PubMedCrossRef

32.

Bruyere, F., Melen-Lamalle, L., Blacher, S., Roland, G., Thiry, M., Moons, L., et al. (2008). Modeling lymphangiogenesis in a three-dimensional culture system. Nature Methods, 5(5), 431–437. https://doi.org/10.1038/nmeth.1205.PubMedCrossRef

33.

Majumder, M., Xin, X., & Lala, P. K. (2013). A practical and sensitive method of quantitating lymphangiogenesis in vivo. Laboratory Investigation, 93(7), 779–791. https://doi.org/10.1038/labinvest.2013.72.PubMedCrossRef

34.

Majumder, M., Tutunea-Fatan, E., Xin, X., Rodriguez-Torres, M., Torres-Garcia, J., Wiebe, R., et al. (2012). Co-expression of alpha9beta1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN. PLoS One, 7(4), e35094. https://doi.org/10.1371/journal.pone.0035094.PubMedPubMedCentralCrossRef

35.

Cao, R., Lim, S., Ji, H., Zhang, Y., Yang, Y., Honek, J., et al. (2011). Mouse corneal lymphangiogenesis model. Nature Protocols, 6(6), 817–826. https://doi.org/10.1038/nprot.2011.359.PubMedCrossRef

36.

Zhang, Z., Helman, J. I., & Li, L. J. (2010). Lymphangiogenesis, lymphatic endothelial cells and lymphatic metastasis in head and neck cancer—a review of mechanisms. International Journal of Oral Science, 2(1), 5–14. https://doi.org/10.4248/IJOS10006.PubMedPubMedCentralCrossRef

37.

Van der Auwera, I., Van Laere, S. J., Van den Eynden, G. G., Benoy, I., van Dam, P., Colpaert, C. G., et al. (2004). Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clinical Cancer Research, 10(23), 7965–7971. https://doi.org/10.1158/1078-0432.CCR-04-0063.PubMedCrossRef

38.

Maula, S. M., Luukkaa, M., Grénman, R., Jackson, D., Jalkanen, S., & Ristamäki, R. (2003 Apr 15). (2003) Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Research, 63(8), 1920–1926.PubMed

39.

Bhattacharjee, R. N., Timoshenko, A. V., Cai, J., & Lala, P. K. (2010). Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer. Cancer Science, 101(9), 2026–2032. https://doi.org/10.1111/j.1349-7006.2010.01647.x.PubMedCrossRef

40.

Song, Y. J., Shin, S. H., Cho, J. S., Park, M. H., Yoon, J. H., & Jegal, Y. J. (2011). The role of lymphovascular invasion as a prognostic factor in patients with lymph node-positive operable invasive breast cancer. Journal of Breast Cancer, 14(3), 198–203. https://doi.org/10.4048/jbc.2011.14.3.198.PubMedPubMedCentralCrossRef

41.

Zheng, W., Aspelund, A., & Alitalo, K. (2014). Lymphangiogenic factors, mechanisms, and applications. The Journal of Clinical Investigation, 124(3), 878–887. https://doi.org/10.1172/JCI71603.PubMedPubMedCentralCrossRef

42.

Timoshenko, A. V., Rastogi, S., & Lala, P. K. (2007). Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. British Journal of Cancer, 97(8), 1090–1098. https://doi.org/10.1038/sj.bjc.6603993.PubMedPubMedCentralCrossRef

43.

Tutunea-Fatan, E., Majumder, M., Xin, X., & Lala, P. K. (2015). The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis. Molecular Cancer, 14, 35. https://doi.org/10.1186/s12943-015-0306-4.PubMedPubMedCentralCrossRef

44.

Simmons, D. L., Botting, R. M., & Hla, T. (2004). Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological Reviews, 56(3), 387–437. https://doi.org/10.1124/pr.56.3.3.PubMedCrossRef

45.

Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10(3), 181–193. https://doi.org/10.1038/nrc2809.PubMedPubMedCentralCrossRef

46.

Howe, L. R. (2007). Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Research, 9(4), 210. https://doi.org/10.1186/bcr1678.PubMedCrossRef

47.

Greenhough, A., Smartt, H. J., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., et al. (2009). The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 30(3), 377–386. https://doi.org/10.1093/carcin/bgp014.PubMedCrossRef

48.

Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011). Regulation of inflammation in cancer by eicosanoids. Prostaglandins & Other Lipid Mediators, 96(1-4), 27–36. https://doi.org/10.1016/j.prostaglandins.2011.08.004.CrossRef

49.

Markovic, T., Jakopin, Z., Dolenc, M. S., & Mlinaric-Rascan, I. (2017). Structural features of subtype-selective EP receptor modulators. Drug Discovery Today, 22(1), 57–71. https://doi.org/10.1016/j.drudis.2016.08.003.PubMedCrossRef

50.

Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001). Prostanoid receptors: subtypes and signaling. Annual Review of Pharmacology and Toxicology, 41, 661–690. https://doi.org/10.1146/annurev.pharmtox.41.1.661.PubMedCrossRef

51.

Fujino, H., Xu, W., & Regan, J. W. (2003). Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. The Journal of Biological Chemistry, 278(14), 12151–12156. https://doi.org/10.1074/jbc.M212665200.PubMedCrossRef

52.

Sugimoto, Y., & Narumiya, S. (2007). Prostaglandin E receptors. The Journal of Biological Chemistry, 282(16), 11613–11617. https://doi.org/10.1074/jbc.R600038200.PubMedCrossRef

53.

O'Callaghan, G., & Houston, A. (2015). Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? British Journal of Pharmacology, 172(22), 5239–5250. https://doi.org/10.1111/bph.13331.PubMedPubMedCentralCrossRef

54.

Buchanan, F. G., Gorden, D. L., Matta, P., Shi, Q., Matrisian, L. M., & DuBois, R. N. (2006). Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 103(5), 1492–1497. https://doi.org/10.1073/pnas.0510562103.PubMedPubMedCentralCrossRef

55.

Konya, V., Marsche, G., Schuligoi, R., & Heinemann, A. (2013). E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacology & Therapeutics, 138(3), 485–502. https://doi.org/10.1016/j.pharmthera.2013.03.006.CrossRef

56.

Rehal, S., Blanckaert, P., Roizes, S., & von der Weid, P. Y. (2009). Characterization of biosynthesis and modes of action of prostaglandin E2 and prostacyclin in guinea pig mesenteric lymphatic vessels. British Journal of Pharmacology, 158(8), 1961–1970. https://doi.org/10.1111/j.1476-5381.2009.00493.x.PubMedPubMedCentralCrossRef

57.

Kashiwagi, S., Hosono, K., Suzuki, T., Takeda, A., Uchinuma, E., & Majima, M. (2011). Role of COX-2 in lymphangiogenesis and restoration of lymphatic flow in secondary lymphedema. Laboratory Investigation, 91(9), 1314–1325. https://doi.org/10.1038/labinvest.2011.84.PubMedCrossRef

58.

Hosono, K., Suzuki, T., Tamaki, H., Sakagami, H., Hayashi, I., Narumiya, S., et al. (2011). Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(5), 1049–1058. https://doi.org/10.1161/ATVBAHA.110.222356.PubMedCrossRef

59.

Hosono, K., Isonaka, R., Kawakami, T., Narumiya, S., & Majima, M. (2016). Signaling of prostaglandin E Receptors, EP3 and EP4 facilitates wound healing and lymphangiogenesis with enhanced recruitment of M2 macrophages in mice. PLoS One, 11(10), e0162532. https://doi.org/10.1371/journal.pone.0162532.PubMedPubMedCentralCrossRef

60.

McDaniel, S. M., Rumer, K. K., Biroc, S. L., Metz, R. P., Singh, M., Porter, W., et al. (2006). Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. The American Journal of Pathology, 168(2), 608–620. https://doi.org/10.2353/ajpath.2006.050677.PubMedPubMedCentralCrossRef

61.

Lyons, T. R., Schedin, P. J., & Borges, V. F. (2009). Pregnancy and breast cancer: when they collide. Journal of Mammary Gland Biology and Neoplasia, 14(2), 87–98. https://doi.org/10.1007/s10911-009-9119-7.PubMedPubMedCentralCrossRef

62.

Lyons, T. R., O'Brien, J., Borges, V. F., Conklin, M. W., Keely, P. J., Eliceiri, K. W., et al. (2011). Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nature Medicine, 17(9), 1109–1115. https://doi.org/10.1038/nm.2416.PubMedPubMedCentralCrossRef

63.

Lyons, T. R., Borges, V. F., Betts, C. B., Guo, Q., Kapoor, P., Martinson, H. A., et al. (2014). Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. The Journal of Clinical Investigation, 124(9), 3901–3912. https://doi.org/10.1172/JCI73777.PubMedPubMedCentralCrossRef

64.

Karnezis, T., Shayan, R., Fox, S., Achen, M. G., & Stacker, S. A. (2012). The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget, 3(8), 893–906. https://doi.org/10.18632/oncotarget.593.PubMedCrossRef

65.

Karnezis, T., Shayan, R., Caesar, C., Roufail, S., Harris, N. C., Ardipradja, K., et al. (2012). VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell, 21(2), 181–195. https://doi.org/10.1016/j.ccr.2011.12.026.PubMedCrossRef

66.

Gogineni, A., Caunt, M., Crow, A., Lee, C. V., Fuh, G., van Bruggen, N., et al. (2013). Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis. PLoS One, 8(7), e68755. https://doi.org/10.1371/journal.pone.0068755.PubMedPubMedCentralCrossRef

67.

Harris, R. E. (Ed.). (2002). COX-2 blockade in cancer prevention and therapy. New York: Springer International publishers.

68.

Liu, C. H., Chang, S. H., Narko, K., Trifan, O. C., Wu, M. T., Smith, E., et al. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. The Journal of Biological Chemistry, 276(21), 18563–18569. https://doi.org/10.1074/jbc.M010787200. PubMedCrossRef

69.

Chulada, P. C., Thompson, M. B., Mahler, J. F., Doyle, C. M., Gaul, B. W., Lee, C., et al. (2000). Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in min mice. Cancer Research, 60(17), 4705–4708.PubMed

70.

Gupta, A. K., & Schoen, R. E. (2009). Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans? Current Opinion in Gastroenterology, 25(1), 59–65. https://doi.org/10.1097/MOG.0b013e32831db286.PubMedCrossRef

71.

Howe, L. R., & Dannenberg, A. J. (2003). COX-2 inhibitors for the prevention of breast cancer. Journal of Mammary Gland Biology and Neoplasia, 8(1), 31–43. https://doi.org/10.1023/a:1025731204719.PubMedCrossRef

72.

Sharpe, C. R., Collet, J. P., McNutt, M., Belzile, E., Boivin, J. F., & Hanley, J. A. (2000). Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. British Journal of Cancer, 83(1), 112–120. https://doi.org/10.1054/bjoc.2000.1119.PubMedPubMedCentralCrossRef

73.

Harris, R. E., Chlebowski, R. T., Jackson, R. D., Frid, D. J., Ascenseo, J. L., Anderson, G., et al. (2003). Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Research, 63(18), 6096–6101.PubMed

74.

Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., et al. (1996). Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87(5), 803–809. https://doi.org/10.1016/s0092-8674(00)81988-1.PubMedCrossRef

75.

Tsujii, M., Kawano, S., & DuBois, R. N. (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences, 94(7), 3336–3340. https://doi.org/10.1073/pnas.94.7.3336.CrossRef

76.

Hida, T., Yatabe, Y., Achiwa, H., Muramatsu, H., Kozaki, K., Nakamura, S., et al. (1998). Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomes. Cancer Research, 58(17), 3761–3764.PubMed

77.

Chan, G., Boyle, J. O., Yang, E. K., Zhang, F., Sacks, P. G., Shah, J. P., et al. (1999). Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Research, 59(5), 991–994.PubMed

78.

Tucker, O. N., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., et al. (1999). Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Research, 59(5), 987–990.PubMed

79.

Parrett, M., Harris, R., Joarder, F., Ross, M., Clausen, K., & Robertson, F. (1997). Cyclooxygenase-2 gene expression in human breast cancer. International Journal of Oncology, 10(3), 503–507. https://doi.org/10.3892/ijo.10.3.503.PubMedCrossRef

80.

Ristimaki, A., Sivula, A., Lundin, J., Lundin, M., Salminen, T., Haglund, C., et al. (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Research, 62(3), 632–635.PubMed

81.

Parhar, R. S., & Lala, P. K. (1985). Changes in the host natural killer cell population in mice during tumor development. Cellular Immunology, 93(2), 265–279. https://doi.org/10.1016/0008-8749(85)90133-9.PubMedCrossRef

82.

Lala, P. K., Parhar, R. S., & Singh, P. (1986). Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cellular Immunology, 99(1), 108–118. https://doi.org/10.1016/0008-8749(86)90220-0.PubMedCrossRef

83.

Lala, P. K., Al-Mutter, N., & Orucevic, A. (1997). Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. International Journal of Cancer, 73(3), 371–380. https://doi.org/10.1002/(sici)1097-0215(19971104)73:3<371::Aid-ijc12>3.0.Co;2-g.PubMedCrossRef

84.

Kundu, N., & Fulton, A. M. (2002). Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Research, 62(8), 2343–2346.PubMed

85.

Rozic, J. G., Chakraborty, C., & Lala, P. K. (2001). Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. International Journal of Cancer, 93(4), 497–506. https://doi.org/10.1002/ijc.1376.PubMedCrossRef

86.

Timoshenko, A. V., Xu, G., Chakrabarti, S., Lala, P. K., & Chakraborty, C. (2003). Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Experimental Cell Research, 289(2), 265–274. https://doi.org/10.1016/S0014-4827(03)00269-6.PubMedCrossRef

87.

Timoshenko, A. V., Lala, P. K., & Chakraborty, C. (2004). PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors. International Journal of Cancer, 108(3), 384–389. https://doi.org/10.1002/ijc.11575.PubMedCrossRef

88.

Xu, L., Stevens, J., Hilton, M. B., Seaman, S., Conrads, T. P., Veenstra, T. D., et al. (2014). COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Science Translational Medicine, 6(242), 242ra284. https://doi.org/10.1126/scitranslmed.3008455.CrossRef

89.

Timoshenko, A. V., Chakraborty, C., Wagner, G. F., & Lala, P. K. (2006). COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. British Journal of Cancer, 94(8), 1154–1163. https://doi.org/10.1038/sj.bjc.6603067.PubMedPubMedCentralCrossRef

90.

Xin, X., Majumder, M., Girish, G. V., Mohindra, V., Maruyama, T., & Lala, P. K. (2012). Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Laboratory Investigation, 92(8), 1115–1128. https://doi.org/10.1038/labinvest.2012.90.PubMedCrossRef

91.

Majumder, M., Xin, X., Liu, L., Girish, G. V., & Lala, P. K. (2014). Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Cancer Science, 105(9), 1142–1151. https://doi.org/10.1111/cas.12475.PubMedPubMedCentralCrossRef

92.

Nandi, P., Girish, G. V., Majumder, M., Xin, X., Tutunea-Fatan, E., & Lala, P. K. (2017). PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells. BMC Cancer, 17(1), 11. https://doi.org/10.1186/s12885-016-3018-2.PubMedPubMedCentralCrossRef

93.

Holt, D., Ma, X., Kundu, N., & Fulton, A. (2011). Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunology, Immunotherapy, 60(11), 1577–1586. https://doi.org/10.1007/s00262-011-1064-9.PubMedCrossRef

94.

Ma, X., Holt, D., Kundu, N., Reader, J., Goloubeva, O., Take, Y., et al. (2013). A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology, 2(1), e22647. https://doi.org/10.4161/onci.22647.PubMedPubMedCentralCrossRef

95.

Okano, M., Sugata, Y., Fujiwara, T., Matsumoto, R., Nishibori, M., Shimizu, K., et al. (2006). E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2. Immunology, 118(3), 343–352. https://doi.org/10.1111/j.1365-2567.2006.02376.x.PubMedPubMedCentralCrossRef

96.

Albu, D. I., Wang, Z., Wu, J., Huang, K.-c., Li, W., Liu, D., et al. (2015). Abstract 275: ER-886046, an antagonist of PGE2 receptor type-4, induces an effective antitumor immune response in mice by attenuating intratumoral MDSCs and TAMs. Cancer Research, 75(15 Supplement), 275–275. https://doi.org/10.1158/1538-7445.Am2015-275.CrossRef

97.

Harizi, H., Grosset, C., & Gualde, N. (2003). Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. Journal of Leukocyte Biology, 73(6), 756–763. https://doi.org/10.1189/jlb.1002483.PubMedCrossRef

98.

Majumder, M., Xin, X., Liu, L., Tutunea-Fatan, E., Rodriguez-Torres, M., Vincent, K., et al. (2016). COX-2 induces breast cancer stem cells via EP4/PI3K/AKT/NOTCH/WNT axis. Stem Cells, 34(9), 2290–2305. https://doi.org/10.1002/stem.2426. PubMedCrossRef

99.

Kundu, N., Ma, X., Kochel, T., Goloubeva, O., Staats, P., Thompson, K., et al. (2014). Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. Breast Cancer Research and Treatment, 143(1), 19–31. https://doi.org/10.1007/s10549-013-2779-4.PubMedCrossRef

100.

Wicha, M. S., Liu, S., & Dontu, G. (2006). Cancer stem cells: an old idea—a paradigm shift. Cancer Research, 66(4), 1883–1890; discussion 1895-1886. https://doi.org/10.1158/0008-5472.CAN-05-3153.PubMedCrossRef

101.

Tysnes, B. B. (2010). Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia, 12(7), 506–515.PubMedPubMedCentralCrossRef

102.

Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M. F., et al. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of the National Cancer Institute, 100(9), 672–679. https://doi.org/10.1093/jnci/djn123.PubMedCrossRef

103.

Visvader, J. E., & Lindeman, G. J. (2012). Cancer stem cells: current status and evolving complexities. Cell Stem Cell, 10(6), 717–728. https://doi.org/10.1016/j.stem.2012.05.007.PubMedCrossRef

104.

Kyzas, P. A., Stefanou, D., & Agnantis, N. J. (2005). COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Modern Pathology, 18(1), 153–160. https://doi.org/10.1038/modpathol.3800244.PubMedCrossRef

105.

Liu, H., Yang, Y., Xiao, J., Lv, Y., Liu, Y., Yang, H., et al. (2010). COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer. Anat Rec (Hoboken), 293(11), 1838–1846. https://doi.org/10.1002/ar.21240.CrossRef

106.

Iwata, C., Kano, M. R., Komuro, A., Oka, M., Kiyono, K., Johansson, E., et al. (2007). Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Research, 67(21), 10181–10189. https://doi.org/10.1158/0008-5472.CAN-07-2366.PubMedCrossRef

107.

Zhang, X. H., Huang, D. P., Guo, G. L., Chen, G. R., Zhang, H. X., Wan, L., et al. (2008). Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer, 8, 4. https://doi.org/10.1186/1471-2407-8-4.PubMedPubMedCentralCrossRef

108.

Pan, M. R., Hou, M. F., Chang, H. C., & Hung, W. C. (2008). Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. The Journal of Biological Chemistry, 283(17), 11155–11163. https://doi.org/10.1074/jbc.M710038200.PubMedCrossRef

109.

Harris, R. E., Beebe-Donk, J., & Alshafie, G. A. (2006). Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer, 6, 27. https://doi.org/10.1186/1471-2407-6-27.PubMedPubMedCentralCrossRef

110.

Fitzgerald, G. A. (2004). Coxibs and cardiovascular disease. The New England Journal of Medicine, 351(17), 1709–1711. https://doi.org/10.1056/NEJMp048288.PubMedCrossRef

111.

Graham, D. J. (2006). COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA, 296(13), 1653–1656. https://doi.org/10.1001/jama.296.13.jed60058.PubMedCrossRef

112.

Yokoyama, U., Iwatsubo, K., Umemura, M., Fujita, T., & Ishikawa, Y. (2013). The prostanoid EP4 receptor and its signaling pathway. Pharmacological Reviews, 65(3), 1010–1052. https://doi.org/10.1124/pr.112.007195.PubMedCrossRef

113.

Cathcart, M. C., Tamosiuniene, R., Chen, G., Neilan, T. G., Bradford, A., O'Byrne, K. J., et al. (2008). Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. The Journal of Pharmacology and Experimental Therapeutics, 326(1), 51–58. https://doi.org/10.1124/jpet.107.134221.PubMedCrossRef

114.

Xiao, C. Y., Hara, A., Yuhki, K. i., Fujino, T., Ma, H., Okada, Y., et al. (2001). Roles of prostaglandin I2 and thromboxane A2 in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation, 104(18), 2210–2215. https://doi.org/10.1161/hc4301.098058.PubMedCrossRef

115.

Martin, M., Meyer-Kirchrath, J., Kaber, G., Jacoby, C., Flogel, U., Schrader, J., et al. (2005). Cardiospecific overexpression of the prostaglandin EP3 receptor attenuates ischemia-induced myocardial injury. Circulation, 112(3), 400–406. https://doi.org/10.1161/CIRCULATIONAHA.104.508333.PubMedCrossRef

116.

Thiemermann, C., & Zacharowski, K. (2000). Selective activation of E-type prostanoid3-receptors reduces myocardial infarct size. Pharmacology & Therapeutics, 87(1), 61–67. https://doi.org/10.1016/s0163-7258(00)00069-3.CrossRef

117.

Hishikari, K., Suzuki, J., Ogawa, M., Isobe, K., Takahashi, T., Onishi, M., et al. (2009). Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. Cardiovascular Research, 81(1), 123–132. https://doi.org/10.1093/cvr/cvn254.PubMedCrossRef

118.

Okumura, Y., Yamagishi, T., Nukui, S., & Nakao, K. (2017). Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. Bioorganic & Medicinal Chemistry Letters, 27(5), 1186–1192. https://doi.org/10.1016/j.bmcl.2017.01.067.CrossRef

119.

Majumder, M., Nandi, P., Omar, A., Ugwuagbo, K. C., & Lala, P. K. (2018). EP4 as a therapeutic target for aggressive human breast cancer. International Journal of Molecular Sciences, 19(4). https://doi.org/10.3390/ijms19041019.

Title: Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer
Authors: Peeyush K. Lala
Pinki Nandi
Mousumi Majumder
Publication date: 01-09-2018
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2-3/2018
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-018-9734-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2018

Role of prostaglandins in tumor microenvironment

Targeting lipid mediators in cancer biology

Role of autotaxin in cancer stem cells

Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications

Omega-3 polyunsaturated fatty acids as adjuvant therapy of colorectal cancer

Functional link between plasma membrane spatiotemporal dynamics, cancer biology, and dietary membrane-altering agents

Keynote webinar | Spotlight on antibody–drug conjugates in cancer